Penumbra (PEN) AI Stock Analysis

• Market Cap: $9.10B
• Dividend Yield: N/A
• Average Volume (3M): 372.77K
• Price to Earnings (P/E): 61.9
• Beta (1Y): 0.48
• Revenue Growth: 12.92%
• EPS Growth: 918.46%
• Country: US
• Employees: 4,500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.86
• Shares Outstanding: 38,999,130
• 10 Day Avg. Volume: 366,921
• 30 Day Avg. Volume: 372,771
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.08
• Enterprise Value/Revenue: 7.71
• Enterprise Value/Gross Profit: 11.60
• Enterprise Value/Ebitda: 50.95
• 1Y Price Target: $309.11
• Price Target Upside: 32.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12

• Rating: 72 Outperform
• Price Target: $281.00 ▲(20.41% Upside)

Penumbra's overall stock score is driven by its strong financial performance and positive earnings call sentiment, highlighting robust revenue growth and strategic initiatives. However, the high P/E ratio and mixed technical indicators suggest caution. The absence of a dividend yield and challenges in international markets also weigh on the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand for Penumbra's products, highlighting the company's ability to expand its market share and drive sales.

U.S. Thrombectomy Business

The robust growth in the U.S. thrombectomy business underscores Penumbra's competitive advantage and strong positioning in a key market segment.

Cash Flow Management

Efficient cash flow management ensures Penumbra can fund operations, invest in R&D, and pursue strategic initiatives without liquidity concerns.

Negative Factors

International Revenue Decline

Declining international revenue, especially in China, poses a risk to Penumbra's global expansion efforts and may impact overall growth.

Challenges in Neurovascular Business

Slower growth in the neurovascular business could limit Penumbra's ability to capitalize on market opportunities, affecting long-term revenue potential.

Gross Margin Sequential Decrease

A sequential decrease in gross margin may indicate pressure on profitability, potentially affecting Penumbra's ability to maintain cost efficiency.

Penumbra Business Overview & Revenue Model

Company Description

Penumbra, Inc. is a global healthcare company specializing in innovative medical devices designed for the treatment of various vascular and neurovascular conditions. The company develops a range of products, including catheter-based devices for thrombectomy, embolization, and other minimally invasive procedures. Penumbra operates primarily in the interventional segment of the medical device industry, focusing on creating solutions that enhance patient outcomes and streamline clinical workflows.

How the Company Makes Money

Penumbra generates revenue through the sale of its medical devices, which are primarily used in hospitals and healthcare facilities for interventional procedures. The company's key revenue streams include the direct sales of its proprietary products, such as thrombectomy devices and other catheter-based interventions. Additionally, Penumbra engages in partnerships with hospitals and healthcare systems to provide comprehensive training and support for its products, further driving sales. The company also benefits from recurring revenue through the sale of disposables and accessories associated with its devices, which are necessary for their operation. Furthermore, ongoing investments in research and development enable Penumbra to expand its product offerings and enter new markets, contributing to its overall earnings.

Penumbra Financial Statement Overview

Summary

Penumbra's financial performance is impressive, with strong revenue growth, improved profitability, and efficient cash management. The company's balance sheet is solid with low leverage, and its cash flow metrics underline robust operational cash generation. Overall, Penumbra's financial health is strong, with consistent improvements across key financial metrics.

Income Statement

Penumbra has shown strong revenue growth, with a TTM revenue increase of 7.2% over the previous year. The gross profit margin is solid at 66.5%, indicating efficient cost management. Net profit margin has improved to 11.5%, reflecting better profitability. EBIT and EBITDA margins also show significant improvement, suggesting enhanced operational efficiency.

Balance Sheet

The company's balance sheet shows a healthy equity ratio of 77.2%, suggesting a strong capital structure with low leverage. The debt-to-equity ratio stands at 0.17, indicating prudent debt management. Return on Equity (ROE) has improved, demonstrating effective use of equity capital to generate profits.

Cash Flow

Penumbra has a robust free cash flow growth rate of 9.7% TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 1.36, highlighting efficient cash conversion from earnings. The free cash flow to net income ratio of 1.09 further supports solid cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.28B	1.19B	1.06B	847.13M	747.59M	560.41M
Gross Profit	850.92M	755.00M	682.64M	535.21M	475.38M	338.18M
EBITDA	193.66M	45.99M	108.65M	29.96M	7.84M	-26.05M
Net Income	147.70M	14.01M	90.95M	-2.00M	5.28M	-15.70M
Balance Sheet
Total Assets	1.67B	1.53B	1.56B	1.37B	1.24B	822.98M
Cash, Cash Equivalents and Short-Term Investments	421.77M	340.13M	289.19M	188.03M	254.88M	264.83M
Total Debt	220.53M	223.39M	234.34M	235.77M	173.55M	77.28M
Total Liabilities	380.86M	382.25M	377.36M	372.03M	290.32M	185.19M
Stockholders Equity	1.29B	1.15B	1.18B	998.86M	953.93M	641.50M
Cash Flow
Free Cash Flow	161.62M	147.30M	82.12M	-74.96M	-11.68M	-58.00M
Operating Cash Flow	201.49M	168.48M	97.33M	-55.66M	9.50M	-33.24M
Investing Cash Flow	8.68M	77.62M	-16.08M	54.79M	-21.73M	-104.15M
Financing Cash Flow	-76.96M	-87.01M	16.20M	11.62M	836.00K	134.92M

Penumbra Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 233.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PEN, the sentiment is Negative. The current price of 233.37 is below the 20-day moving average (MA) of 251.53, below the 50-day MA of 259.05, and below the 200-day MA of 264.01, indicating a bearish trend. The MACD of -4.29 indicates Positive momentum. The RSI at 30.71 is Neutral, neither overbought nor oversold. The STOCH value of 18.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PEN.

Penumbra Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMED	―	$8.30B	23.73	8.62%	―	17.43%	775.48%
PEN	―	$9.10B	61.88	12.03%	―	12.92%	918.46%
IRTC	―	$5.87B	―	-91.13%	―	22.37%	31.14%
LIVN	―	$2.91B	―	-17.87%	―	8.57%	-1154.64%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRCT	―	$2.00B	―	-26.40%	―	55.71%	24.37%
GKOS	―	$4.46B	―	-12.98%	―	26.70%	48.19%

Penumbra Corporate Events

Penumbra Appoints Shruthi Narayan as New President

On August 22, 2025, Penumbra, Inc. appointed Shruthi Narayan as President, effective September 1, 2025. Ms. Narayan, who joined Penumbra in 2013, has been instrumental in building the company’s peripheral vascular division and commercializing its vascular portfolio globally. Her appointment is expected to sustain Penumbra’s growth and market leadership in the medical device industry, particularly in thrombectomy technologies. Adam Elsesser will continue as Chairman and CEO, while Ms. Narayan’s leadership is anticipated to expand access to Penumbra’s life-saving technology worldwide.

The most recent analyst rating on (PEN) stock is a Buy with a $295.00 price target. To see the full list of analyst forecasts on Penumbra stock, see the PEN Stock Forecast page.

Penumbra Inc. Reports Strong Q2 Earnings with Growth in U.S. Thrombectomy

Penumbra Inc.’s recent earnings call painted a picture of robust growth and strategic execution, particularly in the U.S. thrombectomy sector. The company showcased positive momentum with strong revenue growth and promising clinical trial developments. However, challenges in international markets, notably in China, and variability in operating margins due to strategic investments were highlighted as areas of concern.

Penumbra, Inc. Reports Strong Q2 2025 Results

Penumbra, Inc. is a leading company in the medical device industry, specializing in innovative thrombectomy technologies aimed at treating challenging medical conditions such as ischemic stroke and venous thromboembolism. The company operates globally, providing healthcare solutions to improve patient outcomes.